Home/Pipeline/Natriunix Program

Natriunix Program

Rheumatoid Arthritis

Phase 2/3Active

Key Facts

Indication

Rheumatoid Arthritis

Phase

Phase 2/3

Status

Active

Company

XBiotech

About XBiotech

XBiotech's mission is to develop safer, more effective antibody therapies by harnessing natural human immunity, guided by a 'do no harm' principle. Its key achievement was the 2019 sale of its lead IL-1α antibody, bermekimab, for $750M upfront, providing substantial non-dilutive capital. The company's strategy leverages its fully integrated True Human™ platform—encompassing proprietary discovery (SHSAM™), genetic cloning, and in-house manufacturing—to build a pipeline targeting high-need areas in inflammation, oncology, and anti-infectives. XBiotech is now advancing multiple clinical and pre-clinical candidates from its 48-acre Austin campus.

View full company profile

Therapeutic Areas

Oncology Rheumatology Neurology Anti-infectives

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active